For the last few months, I've been watching the debate about the US-China biotech rivalry unfold, and I've been unsatisfied. There are great, smart people arguing about the future of the biotech industry, but too often they're doing it in private, in one-sided online forums, or they're not talking publicly at all. We think that China is the most important story in biotech right now, and that it deserves a better, deeper conversation. So this week in Cambridge, MA, we're hosting the first in a series of debate-style panels and interviews with the industry's most influential voices. On Thursday night, we'll talk about how China (and AI) are changing the nature of innovation, and what it means for the US biotech ecosystem with Strand Therapeutics CEO Jacob Becraft and Roivant CEO Matt Gline. RA Capital founder Peter Kolchinsky, Ginkgo CEO Jason Kelly, and MIT technology and security expert Fiona Murray will debate investor priorities versus the US' industrial capacity needs. And I'll interview Pfizer's Andrew Baum, who serves as senior strategic advisor to the CEO, about pharma's China strategy and its aftereffects. We're also planning a follow-up event in Washington, DC, next month. Our goal with these debates is to take the China biotech issue and break it into pieces. We'll interview more newsmakers and key players, get into discussions about patents, secrecy and work culture, and examine biosecurity issues. Stay tuned for details. This event will take place on Aug. 6, with a happy hour at 5 p.m. and our event starting at 6 p.m., at MIT's Koch Institute For Integrative Cancer Research. It's going to get a bit intense at times, but I can promise we'll all come away smarter. I hope I'll see you there. — Drew Armstrong, Executive Editor P.S. We've had some interest in similar events in San Francisco and New York. The Boston and DC events are being supported by the American Biosecurity Initiative. If you're interested in event sponsorship opportunities to help us put on more of these debates, reach out here and someone from our business side will follow up.